← Back
Data updated: Jun 28, 2026
AOP HLTH US
Pharma Pharmaceuticals
AOP HLTH US is a pharmaceutical company with 1 FDA-approved products.
2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2024) 1 Novel
See 1 novel approval →
AOP HLTH US's Key Drugs
AOP HLTH US's core commercial portfolio centers on RAPIBLYK — its most strategically important drugs approved in the last 15 years.
AOP HLTH US's Recent FDA Approvals
AOP HLTH US secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
AOP HLTH US's Therapeutic Areas
Disease areas where AOP HLTH US has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
AOP HLTH US Pipeline Snapshot
Active clinical trials for AOP HLTH US across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RAPIBLYK leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-11-22
- Latest
- 2026-02-13
- Applications
- 1